Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617227 | 0.91 | ALDH1A1 (0.57) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL245787 | 0.85 | PTPRC (0.54) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL3579270 | 0.84 | PTPRC (0.60) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL3580628 | 0.84 | PTPRC (0.52) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL9734076 | 0.80 | PTPRC (0.63) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL31496742 | 0.80 | PTPRC (0.63) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL179286 | 0.80 | PTPRC (0.63) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL10958370 | 0.80 | PTPRC (0.49) | PTPRCTSHRLMNAACHEALDH1A1 | |
| SCHEMBL2858498 | 0.80 | MEN1 (0.67) | LMNAALDH1A1TDP1KMT2ASMN1; SMN2 | |
| SCHEMBL6621479 | 0.80 | PTPRC (0.48) | PTPRCTSHRLMNAACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024258789-A1 | MODULATORS OF CDK2 AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3902796-B1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| CN-108383836-B | Heterocyclic compounds as MEK inhibitors | 鲁宾有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-113348167-A | (pyridin-2-yl) amine derivatives as TGF-beta R1(ALK5) inhibitors for the treatment of cancer | 奈可萨斯医药有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2834237-B1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LTD (IN) | 2018-06-06 | — | — | EP | disclosed |
| US-9969731-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2018-05-15 | — | — | US | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| WO-2006123145-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-7026357-B2 | Diphenylurea compounds | LES LABORATOIRES SERVIER (FR) | 2006-04-11 | — | — | US | disclosed |
| CN-1241916-C | Novel acardite compound, its preparation method and medicinal composition containing said compound | SERVIER LAB (FR) | 2006-02-15 | — | — | CN | disclosed |
| EP-1170288-B9 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2005-01-26 | — | — | EP | disclosed |
| US-20040224993-A1 | Diphenylurea compounds | LAVIELLE GILBERT (FR) | 2004-11-11 | — | — | US | disclosed |
| US-6784183-B2 | ANTISEROTONINE AGENTS | LES LABORATOIRES SERVIER (FR) | 2004-08-31 | — | — | US | disclosed |
| EP-1170288-B1 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2004-08-11 | — | — | EP | disclosed |
| US-20020025965-A1 | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 2002-02-28 | — | — | US | disclosed |
| EP-1170288-A2 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | PTPRC 1732/4885TSHR 541/4885LMNA 1151/4885 |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | PTPRC 491/4885TSHR 1876/4885LMNA 2716/4885 |
| US-20020025965-A1 | Antiserotonine agents | HTR2C, HTR3C, HTR3A | PTPRC 4196/4885TSHR 271/4885LMNA 445/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | PTPRC 1630/4885TSHR 581/4885LMNA 1501/4885 |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | TGFBR1, TGFBR2, ACVR1 | PTPRC 1732/4885TSHR 541/4885LMNA 1151/4885 |
| US-20040224993-A1 | Diphenylurea compounds | HTR2C, HTR2A, HTR1A | PTPRC 2430/4885TSHR 281/4885LMNA 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.